~~<i id='6C39FB1FE4'><strike id='6C39FB1FE4'><tt id='6C39FB1FE4'><pre id='6C39FB1FE4'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

author：hotspot 2025-09-30 22:10:17 - browse：866

LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

The deal includes up to another $400 million in payments if certain milestones are met.

Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： STAT Virtual Event: ASCO Recap, Live!

knowledge

hotspot

focus

explore

entertainment

ACIP,normallya15-memberpanel,haseightvacancies,andfourmorecomingsoon.Whyhasn'tHHSsignedoffontheCDC's

WSS

What we’ve learned from the Aduhelm mess

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Study: Why relieving medical debt did not improve financial outcomes

Key House Republican on health care plans exit from Congress

Why did Pfizer dish out millions for a Super Bowl ad?

Gilead might be held responsible for not developing a drug

focus

focus

knowledge

What does generative AI mean for health care? We asked experts

Robert F. Kennedy is pitching centrism on health, even on abortion

BioMarin wins approval for gene therapy to treat hemophilia A

Cheap, fast test for Zika and dengue could cost just $1

Jerome Adams on the need for new antivirals for Covid

Moderna says combo Covid

FDA approval of Sarepta Duchenne genetic therapy gives me hope

NIH tests clinical research in primary care with $30 million program

At least 13 dead in Texas as scorching temps continue

The system is set up to fail children with medical complexity

hotspot

To avoid data mishandling cases, universities eye AI and other tools

'Revelatory' study finds a smoking impact that remains after quitting

Statins may not be needed by millions of people, study suggests

Medicare threatens to cut off funding for HCA's Mission hospital

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

My daughter's legacy lives on through her writing, phage therapy

focus

explore

entertainment

entertainment